Comparison of Two Antimalarial Brands on Plasmodium Culture
Abstract
Malaria is a major threat to the public health and economic development of many nations. While P. falciparum causes most malaria-induced mortality worldwide, P. vivax is the major cause of malaria morbidity. In this study we have compared two different brands of Arteether (EMAL and MATCH) for treating P. vivax initially. Arteether™ is a useful drug against chloroquine-resistant P. vivax malaria, without an increased incidence of toxicity. It has a longer half-life and has more lipophilic properties than artemether™, which aids its accumulation in brain tissues for the treatment of cerebral malaria. The study revealed that there was a significant difference in the effectiveness of these two formulations even though they were labeled to have similar indications. These indicate the need for prior examination of these kinds of products for their intended activity. The results of this study have provided evidence to support the better effectiveness of EMAL- brand over MATCH- brand. As EMAL has less viscosity, very good redispersibility, larger zone of inhibition. By observing all of these properties we can conclude that EMAL is a better formulation than MATCH, and can show better antimalarial property in patient suffering from Plasmodium malaria.
Keywords: Antimalarial, Plasmodium species, Zone of inhibition, Indications, Mortality, Half-life
Keywords:
Antimalarial, Plasmodium species, Zone of inhibition, Indications, Mortality, Half-lifeDOI
https://doi.org/10.22270/jddt.v12i6-S.5714References
Miller LH, Good MF, Milon G. Malaria pathogenesis. Science. 1994; 264:1878-1883. https://doi.org/10.1126/science.8009217
Trager W. Living together. The biology of animal parasitism. Plenum Press, New York, N.Y.1986. https://doi.org/10.1007/978-1-4615-9465-9
Beaudoin RL, Mazier D, Hollingdale MR. In vitro cultivation of malaria parasites: exoerythrocytic stages, p. 321-330. In W. H. Wernsdorfer and I. McGregor (ed.), Malaria. Principles and practice of malariology, vol. 1. Churchill Livingstone, Edinburgh, United Kingdom.1988.
Jensen JB. In vitro cultivation of malaria parasites: erythrocytic stages, p. 307-320. In W. H. Wernsdorfer and I. McGregor (ed.), Malaria. Principles and practice of malariology, vol. 1. Churchill Livingstone, Edinburgh, United Kingdom. 1988.
Vanderberg JP. In vitro cultivation of malaria parasites: sporogonic stages, p. 331-347. In W. H. Wernsdorfer and I. McGregor (ed.), Malaria. Principles and practice of malariology, vol. 1. Churchill Livingstone, Edinburgh, United Kingdom.1988.
Hollingdale MR. Is culture of the entire Plasmodium cycle in vitro, now a reality. Parasitol. Today.1992; 8:223. https://doi.org/10.1016/0169-4758(92)90114-H
Anderson RM, May RM Infectious Diseases of Humans. Oxford: Oxford University Press. 1991.
Aron J, May RM. The Population Dynamics of Malaria. In R.M. Anderson (ed.), Population Dynamics and Infectious Disease. London: Chapman and Hall: 1982; 139-79. https://doi.org/10.1007/978-1-4899-2901-3_5
Arrow KJ, Panosian CB, et al., eds. Saving Lives, Buying Time: Economics of Malaria Drug in an Age of Resistance. Board on Global Health. Washington DC: Institute of Medicine. 2004.
Atkinson AB. New Sources of Development Finance. Oxford: Oxford University Press. 2005. https://doi.org/10.1093/0199278555.001.0001
Peters W. The prevention of antimalarial drug resistance. Pharmacology and Therapeutics. 1990; 47: 497-508. https://doi.org/10.1016/0163-7258(90)90067-C
Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulphadoxine: selective pressure is a function of long elimination half-life. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1993; 87:75-78. https://doi.org/10.1016/0035-9203(93)90431-O
Bruce-Chwatt LJ. et al. Chemotherapy of malaria, revised 2nd ed., World Health Organization, Geneva. 1987.
Prasad RN et al. Application of a simplified in vivo test system for determining chloroquine resistance in Plasmodium falciparum. Bulletin of the World Health Organization. 1990; 68:755-75.
Beier J, Killeen G, et al. Short report: entomologic inoculation rates and plasmodium falciparum malaria prevalence in Africa. American Journal of Tropical Medicine and Hygiene. 1999; 61(1):109-13. https://doi.org/10.4269/ajtmh.1999.61.109
A global strategy for malaria control, Geneva, World Health Organization: Geneva, 1993.
Bloland PB et al. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. Journal of Infectious Diseases. 1993; 167(4):932-937. https://doi.org/10.1093/infdis/167.4.932
Bloland PB, Ettling M. Making malaria treatment policy in the face of drug resistance. Annals of Tropical Medicine and Parasitology. 1999; 93(1):5-23. https://doi.org/10.1080/00034983.1999.11813390
Marsh K et al. Malaria disaster in Africa. Lancet. 1998; 352:924. https://doi.org/10.1016/S0140-6736(05)61510-3
Winstanley P, Brekenridge A. Therapeutics and drug development. Lancet. 1997; 349(1):3-4. https://doi.org/10.1016/S0140-6736(97)90064-7
White N. Antimalarial drug resistance and combination chemotherapy. Philosophical Transactions of the Royal Society of London. 1999; B(354):739-749. https://doi.org/10.1098/rstb.1999.0426
White NJ et al. Averting a malaria disaster. Lancet. 1999; 353:1965-1967. https://doi.org/10.1016/S0140-6736(98)07367-X
The use of artemisinin and its derivatives as antimalarial drugs: report of a joint CTD/DMP/TDR informal consultation. Geneva, World Health Organization, 1998 unpublished document WHO/MAL/98.1086)
Krause G et al. Performance of village pharmacies and patient compliance after implementation of an essential drug programme in rural Burkina Faso. Health Policy and Planning. 1998; 13(2):159-166. https://doi.org/10.1093/heapol/13.2.159
Foster SDF. The distribution and use of antimalarial drugs - not a pretty picture. In: Targett GAT, ed. Malaria: waiting for the vaccine. Chichester, John Wiley & Sons Ltd., 1991:123-128
Published
Abstract Display: 355 
PDF Downloads: 427 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.